A scientific statement documenting the findings of a review conducted about the current scientific information available on the symptoms of different cardiovascular diseases has pointed out which symptoms are most common and how symptom presentation varies based on other factors, including age, sex and race, among others. One of the notable observations that the report makes is that it is important to move away from depending on only a physician’s assessment of symptom severity to relying more on self-reported symptom severity because the latter is a more reliable pointer of how serious the cardiovascular disease may be. Self-reported symptoms also offer insights into how the disease is progressing and how much it is affecting the quality of life of the patient.
The research also draws attention to the fact that clinicians and patients need to accord more attention to symptoms that may seem unrelated to the cardiovascular disease (CVD) since such symptoms could point to the existence of that disease or they could signal that the condition has worsened. These symptoms include weight gain, sleep disturbances and fatigue, as well as depression. In some cases, CVD patients presenting with these symptoms may require immediate hospitalization since an acute event may be close to happening.
The report indicates that clinicians need to establish the baseline profile of the symptoms a patient presents with upon diagnosis. Thereafter, the symptoms need to be tracked in order to ascertain how the disease is progressing and how well the patient is responding to the treatment protocol selected by their medical team.
Symptom profiles are also important because not all CVD patients will present with the same symptoms, and some symptoms may develop weeks, months or even years apart. Following up on the self-reported symptoms of patients makes it easy to get a big picture view of how the condition affects the patient’s quality of life and how it is manifesting over time.
Heart attacks were one of the cardiovascular diseases the review team focused upon. They found that chest pain remains the most common symptom of this condition, but their research drew attention to the fact that symptoms such as cold sweats, lightheadedness, unusual fatigue and other similar extra symptoms shouldn’t be looked at as “atypical” because the studies that categorized them as such didn’t include women as study subjects, yet women commonly exhibit those symptoms when they are about to have a heart attack.
It was also noted during the scientific review that men who suffer heart rhythm disorders don’t usually have any symptoms while younger adults as well as women report heart palpitations.
Overall, the report draws attention to many factors that could potentially result in changes being made in the way clinicians assess and monitor patients with CVD. As the noninvasive cardiac monitoring devices made by entities such as Odyssey Health Inc. (OTC: ODYY) become more prevalent, diagnosing cardiovascular diseases early could get easier and patients could start treatment immediately while avoiding the complications that often result when these conditions aren’t detected promptly.
NOTE TO INVESTORS: The latest news and updates relating to Odyssey Health Inc. (OTC: ODYY) are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Brain tumors, such as glioblastoma, are very hard to treat and even surgery isn’t sufficient…
A new study that is being planned by scientists at the University of Calgary, Canada,…
The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…
Izotropic recently published a piece that explores the way AI is redefining breast imaging and…
There is general agreement that the U.S. health care system has issues, but there isn’t…
The closing of the public offering provides the company with critical financial flexibility as it…